. 2005 Jan 13;96(1):31–37. doi: 10.1111/j.1349-7006.2005.00002.x

Table 5.

COX‐2‐immunoreactivity in thyroid preneoplastic and neoplastic lesions in goitrogen‐treated rats after DHPN initiation

Group	Treatments	Week	Focal hyperplasias				Adenomas				Adenocarcinomas invasive to capsules
Group	Treatments	Week	n	(–)	(+)	(++)	n	(–)	(+)	(++)	n	(–)	(+)
1	DHPN + PTU	4	51	48 (94) ^†	3 (6)	0 (0) ^b	2	2 (100)	0 (0)	0 (0)	0
1	DHPN + PTU	10	125	56 (45)	55 (44)	14 (11) ^b	70	43 (61)	25 (36)	2 (3)	0
3	DHPN + SDM	4	69	60 (87)	9 (13)	0 (0) ^a	3	3 (100)	0 (0)	0 (0)	0
3	DHPN + SDM	10	156	101 (65)	55 (35)	0 (0) ^a	50	41 (82)	9 (18)	0 (0)	10	9 (90)	1 (10)

DHPN, N‐bis(2‐hydroxypropyl)nitrosamine; PTU, 6‐propyl‐2‐thiouracil; SDM, sulfadimethoxine; n, number of lesions; ^†percentage; (–), negative; (+), positive in 20–90% cells; (++), positive in >90% cells. Superscript letters indicate significance between values with the same letter: ^a P < 0.01; ^b P < 0.001 (Mann–Whitney's U‐test).